BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32572522)

  • 41. CD34+ selection of hematopoietic blood cell collections and autotransplantation in lymphoma: overnight storage of cells at 4 degrees C does not affect outcome.
    Lazarus HM; Pecora AL; Shea TC; Koç ON; White JM; Gabriel DA; Cooper BW; Gerson SL; Krieger M; Sing AP
    Bone Marrow Transplant; 2000 Mar; 25(5):559-66. PubMed ID: 10713636
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and survival outcomes for bloodless transplantation in patients with myeloma.
    Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR; Graiser M; Heffner LT; Lonial S; Nooka AK
    Cancer; 2019 Jan; 125(2):185-193. PubMed ID: 30480777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation.
    Wuchter P; Ran D; Bruckner T; Schmitt T; Witzens-Harig M; Neben K; Goldschmidt H; Ho AD
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):490-9. PubMed ID: 19925876
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses.
    Suh C; Kim HJ; Kim SH; Kim S; Lee SJ; Lee YS; Kim EK; Kim SB; Lee JS; Kim MW; Kim K; Yoon SS
    Transfusion; 2004 Apr; 44(4):533-8. PubMed ID: 15043569
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Hicks C; Wong R; Manoharan A; Kwan YL
    Ann Hematol; 2007 Aug; 86(8):591-8. PubMed ID: 17492259
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of comorbidity on survival and collected CD34 + cell counts in autologous hematopoietic stem cell transplant patients.
    Sarıcı A; Erkurt MA; Kuku İ; Bahçecioğlu ÖF; Biçim S; Kaya E; Berber İ; Keser MF; Gök S; Özgül M
    Transfus Apher Sci; 2022 Feb; 61(1):103296. PubMed ID: 34696982
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status.
    Chang YJ; Xu LP; Liu DH; Liu KY; Han W; Chen YH; Yu-Wang ; Chen H; Wang JZ; Zhang XH; Zhao XY; Huang XJ
    Biol Blood Marrow Transplant; 2009 May; 15(5):632-8. PubMed ID: 19361756
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors influencing platelet recovery after blood cell transplantation in multiple myeloma.
    Gertz MA; Lacy MQ; Inwards DJ; Pineda AA; Chen MG; Gastineau DA; Tefferi A; Kyle RA; Litzow MR
    Bone Marrow Transplant; 1997 Sep; 20(5):375-80. PubMed ID: 9339752
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The value of the post-thaw CD34+ count with and without DMSO removal in the setting of autologous stem cell transplantation.
    Rohner N; Passweg JR; Tsakiris DA; Halter JP; Heim D; Buser AS; Infanti L; Holbro A
    Transfusion; 2019 Mar; 59(3):1052-1060. PubMed ID: 30556582
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
    Poenisch W; Plötze M; Holzvogt B; Andrea M; Schliwa T; Zehrfeld T; Hammerschmidt D; Schwarz M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Gutsche K; Reifenrath K; Schwarzbach H; Heyn S; Franke GN; Jentzsch M; Leiblein S; Schwind S; Lange T; Vucinic V; AlAli HK; Niederwieser D
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):2013-22. PubMed ID: 25976868
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peripheral blood progenitor cell (PBPC) transplantation with a single apheresis in patients with lymphoma, myeloma and solid tumors.
    Efremidis AP; Koumakis G; Filis J; Moraki M; Vassilomanolakis M; Hatzichristou H; Barbounis V; Stamatellou M; Papanastasiou K; Kritsioti M; Plataniotis G; Arseni P
    Eur J Haematol; 1996 Oct; 57(4):269-77. PubMed ID: 8982289
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Storage Duration of Autologous Stem Cell Preparations Has No Impact on Hematopoietic Recovery after Transplantation.
    Lisenko K; Pavel P; Kriegsmann M; Bruckner T; Hillengass J; Goldschmidt H; Witzens-Harig M; Ho AD; Wuchter P
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):684-690. PubMed ID: 28013016
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.
    Ford PA; Grant SJ; Mick R; Keck G
    J Clin Oncol; 2015 May; 33(15):1674-9. PubMed ID: 25870085
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.
    Sun L; Li S; El-Jawahri A; Armand P; Dey BR; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; McAfee SL; Spitzer TR; Chen YB; DeFilipp Z
    Oncologist; 2018 May; 23(5):624-630. PubMed ID: 29284757
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictive factors for long-term engraftment of autologous blood stem cells.
    Duggan PR; Guo D; Luider J; Auer I; Klassen J; Chaudhry A; Morris D; Glück S; Brown CB; Russell JA; Stewart DA
    Bone Marrow Transplant; 2000 Dec; 26(12):1299-304. PubMed ID: 11223969
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of CD34+ cell dose on platelet engraftment in pediatric patients following unmanipulated haploidentical blood and marrow transplantation.
    Chang YJ; Xu LP; Liu DH; Liu KY; Han W; Chen YH; Wang Y; Chen H; Wang JZ; Zhang XH; Zhao XY; Huang XJ
    Pediatr Blood Cancer; 2009 Dec; 53(6):1100-6. PubMed ID: 19743519
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-dose CD34+ cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose.
    Lefrère F; Delarue R; Somme D; Levy V; Damaj G; Tu A; Porcher R; Audat F; Boulat C; Cavazzana-Calvo M; Buzyn A; Belanger C; Maillard N; Hermine O; Varet B
    Transfusion; 2002 Apr; 42(4):443-50. PubMed ID: 12076291
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma.
    Keruakous AR; Asch A; Aljumaily R; Zhao D; Yuen C
    Transpl Immunol; 2022 Apr; 71():101544. PubMed ID: 35093506
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis.
    Gandhi M; Jestice H; Scott M; Bloxham D; Bass G; Craig J; Marcus R
    Bone Marrow Transplant; 1999 Aug; 24(4):369-75. PubMed ID: 10467325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.